A Trace ‘Tides Primer: Understanding the human cathelicidin peptide

By: Laura Mildon

LL-37 is a naturally occurring peptide containing 37 amino acids. It is part of the human cathelicidin system, which researchers investigate in innate immunity and cellular signaling. Its name refers to the two leucine residues at the beginning of its sequence and the total number of residues.

Published research examines antimicrobial activity, interactions with host cells, and responses that vary with the biological setting. Those findings do not establish a benefit or intended use for a commercial research material.

What cathelicidin means

Cathelicidins are a family of proteins that contain a related precursor region and a distinct peptide region. The human precursor is commonly called hCAP18 or hCAP-18. Enzymatic cleavage of that precursor can release LL-37.

A precursor is a larger molecule from which another molecule is produced. A protease is an enzyme that cuts protein chains. The precursor and the released peptide have different identities and should not be treated as interchangeable experimental materials.

Chemical identity

The formula and weight describe the peptide entity in the cited record. Salt counterions, hydration, sequence changes, and terminal modifications require separate identification. A database record does not authenticate a supplied material.

PubChem sequence and chemical identity

Understanding innate immunity

Innate immunity includes defense mechanisms that respond to biological challenges without requiring prior exposure to the same target. LL-37 is studied as a host-defense peptide, but that label does not imply that every effect is protective.

A peptide can interact with microbes and with host cells. The outcome may depend on the cell type, surrounding proteins, membrane composition, and other experimental conditions. Antimicrobial activity in a laboratory assay does not demonstrate an effective treatment in people.

History and discovery

The research history developed in stages. In 1995, Gudmundsson and colleagues described FALL-39, a proposed peptide sequence predicted from a human bone-marrow cDNA clone. In 1996, the same research lineage reported processing of the precursor and the 37-residue peptide LL-37 in granulocytes, a group of immune cells.

This distinction separates an early sequence prediction from characterization of the processed peptide. A 2001 study subsequently investigated the enzyme and cellular setting responsible for releasing LL-37 from hCAP18.

Early FALL-39 sequence report 1995

Precursor processing and LL-37 characterization 1996

Selected published research

LL-37 is not FDA-approved as a medicine. These selected studies describe biological mechanisms and experimental observations; they do not establish clinical effectiveness or an intended use for a research product.

Antimicrobial assays in 1998

Turner and colleagues compared LL-37 with other antimicrobial peptides using laboratory assays. The study investigated activity against microorganisms under defined testing conditions.

Such assays help characterize a peptide’s behavior, but their results depend on the organisms and assay environment. They do not establish broad clinical infection control, human safety, or equivalent activity for every preparation.

Turner and colleagues in Antimicrobial Agents and Chemotherapy 1998

Release from the precursor in 2001

Sørensen and colleagues investigated how hCAP18 is processed to release LL-37. Their work identified extracellular cleavage by proteinase 3 after neutrophil exocytosis, the release of cellular granule contents.

This study explains a mechanism of endogenous peptide production in a particular cellular setting. It does not establish that an externally supplied research peptide reproduces the regulation or behavior of the natural precursor system.

Sørensen and colleagues in Blood 2001

Host cell signaling in a cancer model in 2008

Von Haussen and colleagues examined LL-37/hCAP18 in lung-cancer tissue, cancer cell lines, and mouse experiments. They reported enhanced growth-related signaling in cell models and greater tumor growth in a model involving increased cathelicidin expression.

These results show why host-defense biology should not be summarized as uniformly beneficial. They do not prove that LL-37 causes cancer in people, but they make the tissue and experimental context essential to interpretation.

Von Haussen and colleagues in Lung Cancer 2008

Molecular structure

The sequence specifies the amino acid order; the molecular formula only counts atoms. PubChem provides a two-dimensional chemical depiction for the identified peptide. A chemical connectivity diagram should not be described as one fixed three-dimensional shape under all conditions.

What remains unresolved

LL-37 has a substantial experimental literature, but individual findings address different questions. An antimicrobial assay, a change in inflammatory signaling, and an observation in a tumor model are not interchangeable outcomes.

The selected studies do not establish long-term human safety or generalized claims about infection prevention, immune enhancement, recovery, or tissue repair. Findings involving hCAP18 expression also need to be distinguished from experiments using the isolated LL-37 peptide.

Chemical identity and material characterization remain important. A shortened fragment, modified analogue, salt form, or blend should not be assumed to reproduce the behavior of the specified peptide in a published experiment.

Regulatory context

FDA identifies cathelicidin LL-37 among bulk substances for compounding that may present significant safety risks. Its notice highlights possible immune responses, peptide-related impurities, and challenges in characterizing the active ingredient. FDA states that it lacks sufficient safety information.

The notice also identifies nonclinical findings suggesting detrimental effects on male reproduction and tumor-promoting activity in some tissues. Nonclinical findings warrant careful interpretation; they are not proof of the same outcome in people.

This notice concerns drug compounding and safety uncertainty. It should not be described as a blanket prohibition on laboratory research. Research labeling does not establish FDA approval, clinical safety, or permission for another intended use.

FDA notice on cathelicidin LL-37 and compounding risks

Research and regulatory sources checked October 13, 2026.

DISCLAIMER: These statements are for research purposes only and have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why choose Trace 'Tides? 

Because trust starts with real people, clear answers, and quality you can verify. We have a certified peptide specialist on staff, a phone number that connects you with a real human, and a physical location you can visit by appointment. Call or text us—we’re delighted to answer your questions and address your concerns. We also make checkout straightforward by accepting credit cards, without asking you to use cryptocurrency or connect your bank account to an unfamiliar payment app. And every peptide we sell is tested for purity and endotoxins by licensed U.S. laboratories, so you can choose your research peptides with confidence.